Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

.................and so we enter the fourth year of the hype that is BPRG.

;-)))))))

AL, It seems they must be listening to you.

Should increase the price a little. I have waited long enough.

BioProgress sees two tablet coating developments generating revenues in 2007
AFX


LONDON (AFX) - BioProgress PLC said the first TabWrap tablet-coating machine, one of the company's core experimental technologies, will be placed in a certified manufacturing facility in the last quarter of the year for initial testing.

At the same time the speciality pharma and healthcare company announced it has developed a new enteric (relating to the intestines) tablet-coating system, called EntWrap.

The company predicted that both developments will generate revenues next year. It plans to market the products itself or in partnership with other pharmaceutical companies.

TabWrap coats solid tablet cores with a non-gelatin layer of film called XGEL, and will compete against the gelatin-coated tablet market.

The company, which says it is working with a number of 'leading pharmaceutical companies' in developing products utilising the TabWrap, will start stability trials in the first half of next year.

Meanwhile the market potential for enteric coated tablets, a key component for a number of prescription medicines, is significantly greater than the gelatin coating market, BioProgress said.

Enteric coatings enable tablets to pass through the acidic stomach environment and into the intestines, where active ingredients can be more rapidly absorbed.

The coating system uses both XGEL and TabWrap technology, which the company claimed will have a number of significant advantages over current enteric coating processes.

'The development of EntWrap widens the market opportunity for BioProgress,' chief executive Richard Trevillion said in a statement.

'With the installation of the first TabWrap machine later this year, we anticipate an aggressive development program of products.'

AIM-listed BioProgress shares closed Tuesday at 46 pence, valuing the company at 65 mln stg.

amy.brown@afxnews.com


UK smallcap opening - BioProgress up on enabling technology update
AFX


LONDON (AFX) - BioProgress moved up 3 pence to 49 after the speciality pharma and healthcare company revealed it has developed a novel enteric tablet-coating system, EntWrap.

Additionally, the company said the first TabWrap tablet-coating machine is due to be placed into a cGMP pharmaceutical tablet manufacturing facility within the UK in Q4 2006 for a series of initial validation tests.

Following the news, Bridgewell's Chris Millington reiterated his 'buy' recommendation, pointing out that there is still upside to go to his 57 pence fair value on the stock.

newsdesk@afxnews.com

fjb/vjt

Can somebody list all the 'unsuitable' executives that have progressed through BPRG's revolving doors in last year or so, preferably those carrying large bags with them.

Interesting information on Web. It will very nice if this is true.

http://www.bioprogress.com/news/article.php?News_ID=521462

CFO resignation is yet another careless moment. The company seems to have bumbled along from 1 problem to another for so long.

Come along Big Al, come clean and tell us that you hold some BPRG :)

No-one here seems to have commented on the interim statements which were intriguing indeed. Enough to persuade me to re-invest at 47p after a couple of years out.

Interim statement here

The business is very differently structured now from its overblown days under Graham Hind. To me it looks like there's more realism and substance about it.

The likeness between Spinal Tap's drummers and BPRG's FDs is the one concern I guess!

See you hopefully at the Xmas gig!

Hi Bones.

Never did buy them. Old habits die hard I guess. ;-) Must agree the company is a very different animal these days. Wonder if the shareholders are. LOL! I get the impression there's no rush to jump in however, so we'll see.

Best of luck with it.

Over recent months share price is moving in the right direction. (for me I am long)

I think it is going to continue its uptrend at a more rapid speed.



News Article
Appointment of distributor for HypoSalix
05/10/2006
London, UK, 5 October 2006: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, is pleased to announce a new distributor for its recently registered artificial saliva spray, HypoSalix.
DEM Pharmaceuticals in Istanbul, Turkey have been appointed BioProgress's official distributor of Hyposalix for Turkey. The agreement is managed through BioProgress"s French operation, Dexo SA. The terms of the agreement are not disclosed
Hyposalix is a medical device for the treatment of xerostomia, and a key element in the BioProgresss strategy of developing products for its Patient Supportive Care franchise.
Steve Martin, Chief Development Officer, BioProgress, said:
"The licensing of HypoSalix to a partner is a key milestone in BioProgresss commercialisation strategy of its products. HypoSalix has been recently registered and received a great deal of interest world wide. Turkey is an important and fast growing market and we believe that DEM Pharmaceuticals will be a solid partner in marketing our Patient Supportive Care franchise.
For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEOSteve Martin, CDO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

Hmm Fred, it's a pity it takes them 13 days to email the RNS's to registered people! I got that this morning too but read it on MAM on 5th October.

No problem though, the chart is behaving extremely positively while we await some developments. Big resistance area coming up. The range from 58p to 70p has always been an active area between buyers and sellers.

Yep, +/-60p the biggie, Bones

Interesting close today Bones. ;-)))

Yes, Big Al. Another last 1/2 hour flurry which has been the pattern all week. When the interims came out, Mr Private Investor was nowhere to be seen but the CEO has done the rounds with the City boys in the last two weeks. I would think there has been some institutional buying to cause these daily 2 or 3 point tick ups. It's been orderly and no sign of hysteria...........so far! Long may it continue

And so it continues to tick up

A surprise Xmas present is rumoured to be on its way from R. Trevellion. The guy delivers, so it could be very nice.

With some positive product news, BPRG has performed well over the last 6 months. The products have real mass market potential.

A little info which you may not be aware of:-

BioProgress at Arab Health 2007

25/01/2007

London, UK, 25 January 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare announces that it will be showing its technologies and products at Arab Health, Dubai on 29 January - 01 February.

Arab Health is attended by over 33,000 visitors with 2,200 exhibiting companies. With many of the global and regional pharmaceutical companies attending, Arab Health 2007 offers BioProgress a central forum targeting a global audience. We plan to extend our strategic relationships, and target additional distributors for our current portfolio of over 40 pharmaceutical and healthcare products, and five commercialised enabling systems.

For more details on Arab Health 2007, visit www.arabhealthonline.com.

Steve Martin, Chief Development Officer said:

"Arab Health is an important forum to show our products and technologies to a wide global audience. This is the first time we have shown at Arab Health and represents a significant step forward for the company where we are showcasing over 40 products, and a range of unique enabling drug delivery systems.

For further information:

BioProgress Plc

+ 44 (0) 20 7098 9881
kim

Looks a bit toppy to me.

;-)

Ignore Al .... wind up merchant

:-)

News Article
Operational Board Update and Appointment

01/02/2007

London, UK, 1 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, today announces the creation of a new executive operational board for the Company, and the appointment of Keith Hemming, as Head of Operations, a new position within the management team of BioProgress.

The operational board will be responsible for the day to day management of the Group. This has become necessary as the number of new development projects both for partners and for the Company's own pharmaceutical division is increasing substantially due to positive validation work and the adoption of a number of BioProgress"s enabling systems. At the same time the core pharmaceutical division Dexo is undergoing rapid growth in all of its territories. This underlying organic growth validates the Companys product led strategy and creates the resource necessary for continued substantial growth.

Keith Hemming, the new Head of Operations, has over twenty years experience in the Pharmaceutical industry, holding senior marketing and General Management positions with Squibb, Yamanouchi, and most recently as President UK Operations for Fujisawa Pharma, member of the Fujisawa European senior management team. Prior to this he was with Astellas Pharmaceuticals Global Licensee Division working on European strategy and implementation. During his career he launched Flomax and Protopic in the UK, and took Prograf, an immunosuppressant, to market leadership.

Keith was a member of the Board of Management of the Association of British Pharmaceutical Industry (ABPI) for four years, and member of the UK Pharmaceutical Code of Practice Appeal Board.

He was also founder and first Chair of the UK Japanese Pharmaceutical Group associated to the Japanese Pharmaceutical Manufacturers Association (JPMA), and Chair of the Industry Group for the National Health Service Framework for Renal Services.

Richard Trevillion, Chief Executive Officer, BioProgress Plc, said:

"We are pleased to welcome Keith to the operational management team. Keith has substantial experience in sales and marketing and in managing high growth late stage pharmaceutical product development. His knowledge of the Japanese pharmaceutical industry is also welcome as BioProgress increases its marketing activity within Japan.

Keith Hemming, Head of Operations, said:

I am delighted to be joining BioProgress at such an exciting stage in the Companys development. The recent increase in activity is testament to the strength of the core enabling systems which are contributing to a strong product development pipeline. The resulting rapid growth in the Dexo pharmaceutical sales and marketing division validates the product led speciality pharmaceutical model that BioProgress is proactively pursuing.

This company seems to be heading in the right direction at last.
kim